The new pancreatic cancer drug "Onivyde" is in the final stages of listing insurance benefits.

According to related industries, Servier Korea has recently entered pharmaceutical negotiations with the NHIS for the registration of Onivyde (Irinotecan HCl) under the order of the MOHW. As a result, attention is being paid to whether a new insurance benefit application drug can be created in the area of pancreatic cancer, which does not have many treatments.

Onivyde's application for benefits, which passed the HIRA's Pharmaceutical Benefits Advisory Committee on the 8th of last month, was approved. It is a combination of 5-FU/LV and secondary treatment in patients who fail Gemcitabine based pr